NASDAQ:IOVA - Iovance Biotherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.00
  • Forecasted Upside: 65.46 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$24.78
▲ +0.16 (0.65%)
1 month | 3 months | 12 months
Get New Iovance Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IOVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IOVA

Average Price Target: $41.00
▲ +65.46% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is $41.00, with a high forecast of $55.00 and a low forecast of $18.00. The average price target represents a 65.46% upside from the last price of $24.78.

Buy

The current consensus among 13 polled investment analysts is to buy stock in Iovance Biotherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/27/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/26/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/24/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/22/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/20/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/10/2021JMP SecuritiesUpgradeMarket Perform ➝ Outperform$32.00High
5/26/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$35.00 ➝ $18.00Low
5/25/2021OppenheimerLower Price TargetOutperform$51.00 ➝ $38.00N/A
5/20/2021Robert W. BairdLower Price TargetOutperform$55.00 ➝ $35.00High
5/20/2021MizuhoBoost Price TargetBuy$30.00 ➝ $55.00High
5/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$35.00 ➝ $18.00High
5/19/2021Stifel NicolausDowngradeBuy ➝ HoldHigh
5/19/2021Chardan CapitalLower Price TargetBuy$54.00 ➝ $51.00High
5/19/2021OppenheimerLower Price TargetOutperform$57.00 ➝ $51.00High
5/19/2021JMP SecuritiesLower Price TargetOutperform ➝ Market Perform$45.00 ➝ $43.00High
5/19/2021BarclaysLower Price TargetOverweight$60.00 ➝ $40.00High
5/19/2021HC WainwrightLower Price TargetBuy$50.00 ➝ $46.00High
5/19/2021Piper SandlerLower Price TargetOverweight$45.00 ➝ $35.00High
5/3/2021Truist SecuritiesInitiated CoverageBuy$50.00Low
5/3/2021TruistInitiated CoverageBuy$50.00Low
4/16/2021The Goldman Sachs GroupInitiated CoverageBuyHigh
3/8/2021HC WainwrightUpgradeNeutral ➝ Buy$50.00High
3/1/2021Chardan CapitalReiterated RatingBuyHigh
1/14/2021OppenheimerBoost Price TargetOutperform$43.00 ➝ $57.00Medium
12/17/2020BarclaysBoost Price TargetPositive ➝ Overweight$43.00 ➝ $55.00Low
12/15/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
11/9/2020JMP SecuritiesBoost Price TargetMarket Outperform$38.00 ➝ $45.00Low
11/6/2020BarclaysBoost Price TargetOverweight$36.00 ➝ $43.00Medium
11/6/2020Piper SandlerBoost Price TargetOverweight$35.00 ➝ $45.00Medium
10/15/2020Wells Fargo & CompanyBoost Price TargetEqual Weight ➝ Equal Weight$29.00 ➝ $35.00High
10/6/2020Stifel NicolausLower Price Target$47.00 ➝ $42.00High
10/6/2020BarclaysLower Price TargetOverweight$45.00 ➝ $36.00High
10/6/2020HC WainwrightLower Price TargetBuy$48.00 ➝ $46.00High
10/6/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$49.00 ➝ $29.00High
10/6/2020OppenheimerReiterated RatingBuy$43.00High
10/6/2020Chardan CapitalReiterated RatingBuy$53.00 ➝ $50.00High
8/7/2020Chardan CapitalBoost Price TargetBuy$44.00 ➝ $53.00High
8/7/2020OppenheimerReiterated RatingBuy$43.00High
6/15/2020OppenheimerInitiated CoverageBuy$43.00Low
5/28/2020Stifel NicolausBoost Price TargetBuy$48.00 ➝ $50.00High
5/27/2020Chardan CapitalReiterated RatingBuyHigh
5/14/2020Chardan CapitalReiterated RatingBuy$44.00Medium
5/6/2020Robert W. BairdBoost Price TargetOutperform$60.00 ➝ $65.00Medium
5/5/2020OppenheimerInitiated CoverageBuy$43.00Low
5/5/2020MizuhoReiterated RatingBuy$61.00Low
4/29/2020HC WainwrightBoost Price TargetPositive ➝ Buy$36.00 ➝ $48.00High
4/28/2020OppenheimerInitiated CoverageBuy$35.00 ➝ $43.00High
4/27/2020Chardan CapitalBoost Price TargetBuy$36.00 ➝ $44.00High
4/27/2020MizuhoReiterated RatingBuy$61.00Low
4/21/2020MizuhoInitiated CoverageBuyLow
3/4/2020BarclaysInitiated CoverageOverweight$45.00Medium
2/26/2020Piper SandlerBoost Price TargetOutperform$40.00Medium
2/26/2020Chardan CapitalReiterated RatingBuy$36.00Medium
2/26/2020OppenheimerReiterated RatingOutperform$32.00 ➝ $35.00High
2/26/2020CowenReiterated RatingBuyHigh
2/26/2020HC WainwrightBoost Price TargetBuy$32.00 ➝ $36.00High
2/26/2020Wells Fargo & CompanyBoost Price TargetOverweight$32.00 ➝ $38.00High
1/13/2020CowenInitiated CoverageBuyHigh
12/18/2019JMP SecuritiesInitiated CoverageOutperform$38.00Medium
11/21/2019HC WainwrightReiterated RatingBuy$32.00High
11/21/2019Chardan CapitalReiterated RatingBuy$33.00High
11/8/2019Chardan CapitalReiterated RatingBuy$33.00High
11/5/2019HC WainwrightReiterated RatingBuy$32.00High
9/30/2019Stifel NicolausInitiated CoverageBuy$27.00Low
8/26/2019Jefferies Financial GroupSet Price TargetBuy$33.00Low
8/16/2019B. RileySet Price TargetBuy$28.00Medium
7/3/2019OppenheimerSet Price TargetBuy$32.00Low
7/2/2019HC WainwrightReiterated RatingBuy$32.00Medium
6/28/2019Piper Jaffray CompaniesBoost Price TargetOverweight$20.00 ➝ $30.00High
6/3/2019Jefferies Financial GroupBoost Price TargetBuy$29.00 ➝ $33.00High
6/3/2019UBS GroupBoost Price TargetOutperform$25.00 ➝ $30.00Medium
6/3/2019HC WainwrightBoost Price TargetBuy$26.00 ➝ $32.00High
5/31/2019Chardan CapitalReiterated RatingBuy$30.00High
5/23/2019HC WainwrightReiterated RatingBuy$26.00Low
5/23/2019Wells Fargo & CompanyBoost Price TargetOutperform$23.00 ➝ $32.00Low
5/20/2019Chardan CapitalSet Price TargetBuy$30.00Medium
5/17/2019B. RileySet Price TargetBuy$24.00Medium
5/16/2019Robert W. BairdBoost Price TargetOutperform$29.00 ➝ $34.00Medium
4/29/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$20.00High
4/23/2019Chardan CapitalReiterated RatingBuyHigh
4/5/2019B. RileyReiterated RatingBuyLow
4/2/2019Chardan CapitalReiterated RatingBuy$20.00High
4/1/2019HC WainwrightReiterated RatingBuy$26.00Low
3/19/2019OppenheimerReiterated RatingBuyLow
3/13/2019Chardan CapitalReiterated RatingBuyMedium
2/28/2019Chardan CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $20.00High
2/6/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$29.00 ➝ $29.00High
1/11/2019OppenheimerSet Price TargetBuy$25.00Low
12/31/2018B. RileyInitiated CoverageBuy ➝ Buy$24.00 ➝ $24.00Medium
11/12/2018HC WainwrightReiterated RatingBuy$26.00High
11/6/2018CowenReiterated RatingBuyHigh
10/12/2018HC WainwrightReiterated RatingBuy$22.00 ➝ $26.00High
10/12/2018CitigroupBoost Price TargetPositive ➝ Outperform$22.00 ➝ $25.00High
9/25/2018HC WainwrightReiterated RatingBuy$22.00High
9/6/2018HC WainwrightSet Price TargetBuy$22.00High
8/7/2018HC WainwrightSet Price TargetBuy$22.00High
7/6/2018Chardan CapitalReiterated RatingBuy$30.00High
6/13/2018HC WainwrightSet Price TargetBuy$22.00High
5/11/2018B. RileyBoost Price TargetBuy ➝ Buy$22.00 ➝ $24.00Low
5/11/2018HC WainwrightReiterated RatingBuy$22.00High
4/10/2018B. RileyUpgradeNeutral ➝ Buy$22.00Low
3/13/2018HC WainwrightSet Price TargetBuy$22.00High
3/13/2018B. RileyBoost Price TargetNeutral ➝ Neutral$18.50 ➝ $22.00High
2/23/2018B. RileyReiterated RatingBuy ➝ Neutral$18.00 ➝ $18.50High
2/9/2018Jefferies Financial GroupBoost Price TargetBuy$31.00Low
2/8/2018HC WainwrightSet Price TargetBuy$22.00High
1/31/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$13.00 ➝ $19.00Low
1/29/2018Wells Fargo & CompanyReiterated RatingBuy$23.00Medium
1/25/2018B. RileyReiterated RatingBuy$18.00Medium
1/25/2018HC WainwrightBoost Price TargetBuy ➝ Buy$16.00 ➝ $22.00High
1/22/2018Chardan CapitalReiterated RatingBuyHigh
1/17/2018HC WainwrightSet Price TargetBuy$16.00High
12/14/2017HC WainwrightSet Price TargetBuy$16.00High
12/14/2017OppenheimerSet Price TargetBuy$13.00High
12/13/2017B. RileyReiterated RatingBuy$18.00Low
11/13/2017HC WainwrightReiterated RatingBuy$16.00N/A
11/13/2017B. RileyReiterated RatingBuy$18.00N/A
11/13/2017OppenheimerReiterated RatingBuy$13.00N/A
11/1/2017B. RileyBoost Price TargetBuy$17.50 ➝ $18.00N/A
10/31/2017OppenheimerSet Price TargetBuy$13.00N/A
10/30/2017HC WainwrightSet Price TargetBuy$16.00N/A
10/29/2017Jefferies Financial GroupReiterated RatingBuyN/A
10/25/2017(FBRC)Reiterated RatingBuy$17.50N/A
10/12/2017OppenheimerSet Price TargetBuy$13.00N/A
9/26/2017OppenheimerReiterated RatingBuy$13.00Low
9/13/2017HC WainwrightReiterated RatingBuy$16.00High
9/11/2017OppenheimerSet Price TargetBuy$13.00Low
9/7/2017Chardan CapitalReiterated RatingBuyHigh
9/5/2017Jefferies Financial GroupReiterated RatingBuy$11.00High
9/1/2017Chardan CapitalReiterated RatingBuy$20.00High
8/31/2017HC WainwrightReiterated RatingBuy$16.00Medium
8/18/2017OppenheimerSet Price TargetBuy$13.00Low
8/16/2017CowenReiterated RatingBuyMedium
8/16/2017HC WainwrightReiterated RatingBuy$16.00High
8/4/2017OppenheimerInitiated CoverageOutperform$13.00High
6/7/2017HC WainwrightReiterated RatingBuy$16.00Low
6/6/2017CowenReiterated RatingBuyLow
5/20/2017CowenReiterated RatingBuyHigh
5/18/2017(FBRC)Reiterated RatingBuyHigh
5/18/2017Jefferies Financial GroupReiterated RatingBuy$11.00Low
5/17/2017Chardan CapitalReiterated RatingBuyHigh
5/10/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$13.00Low
5/4/2017Chardan CapitalBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00High
4/19/2017CowenReiterated RatingBuyMedium
4/17/2017Chardan CapitalReiterated RatingBuyLow
3/17/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformHigh
3/8/2017Roth CapitalSet Price TargetBuy$14.00Low
3/8/2017(FBRC)Set Price TargetBuy$17.00Low
3/8/2017Jefferies Financial GroupLower Price TargetBuy$13.00 ➝ $11.00Low
2/15/2017Roth CapitalReiterated RatingBuyN/A
1/11/2017(FBRC)Set Price TargetBuy$18.00N/A
11/28/2016Roth CapitalReiterated RatingBuy$15.00N/A
11/7/2016Jefferies Financial GroupReiterated RatingBuy$13.00N/A
11/4/2016CowenReiterated RatingBuyN/A
8/26/2016Roth CapitalReiterated RatingBuy$15.00N/A
8/21/2016Chardan CapitalSet Price TargetBuy$20.00N/A
7/9/2016Roth CapitalReiterated RatingBuy$15.00N/A
(Data available from 6/20/2016 forward)
Iovance Biotherapeutics logo
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $24.78
Low: $24.10
High: $25.11

50 Day Range

MA: $25.23
Low: $16.33
High: $33.07

52 Week Range

Now: $24.78
Low: $15.88
High: $54.21

Volume

3,392,314 shs

Average Volume

2,786,432 shs

Market Capitalization

$3.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Iovance Biotherapeutics?

The following Wall Street research analysts have issued reports on Iovance Biotherapeutics in the last twelve months: Barclays PLC, Chardan Capital, HC Wainwright, JMP Securities, Mizuho, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist, Truist Securities, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for IOVA.

What is the current price target for Iovance Biotherapeutics?

12 Wall Street analysts have set twelve-month price targets for Iovance Biotherapeutics in the last year. Their average twelve-month price target is $41.00, suggesting a possible upside of 65.5%. Mizuho has the highest price target set, predicting IOVA will reach $55.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $18.00 for Iovance Biotherapeutics in the next year.
View the latest price targets for IOVA.

What is the current consensus analyst rating for Iovance Biotherapeutics?

Iovance Biotherapeutics currently has 3 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IOVA will outperform the market and that investors should add to their positions of Iovance Biotherapeutics.
View the latest ratings for IOVA.

What other companies compete with Iovance Biotherapeutics?

How do I contact Iovance Biotherapeutics' investor relations team?

Iovance Biotherapeutics' physical mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company's listed phone number is (650) 260-7120 and its investor relations email address is [email protected] The official website for Iovance Biotherapeutics is www.iovance.com.